- Active Pharmaceutical Ingredients
- Varenicline tartrate
- Aprepitant, Fosapitant Intermediates
- Fosaprepitant Dimeglumine
- Vildagliptin
- Efinaconazole
- Luliconazole Intermediate
- Gadoterate Meglumine
- Succinyl Alcohol Intermediate
- Mirabillon Intermediate
- Atazanavir Intermediate
- Intermediate
- Varenicline tartrate
- Aprepitant 287930-73-8
- Aprepitant 127852-28-2
- Aprepitant 287930-75-0
- Aprepitant 200000-59-5
- Aprepitant 155742-64-6
- Aprepitant 252742-72-6
- Fosaprepitant Dimeglumine 990-91-0
- Fosaprepitant Dimeglumine 265121-01-5
- Vildagliptin 207557-35-5
- Vildagliptin 702-82-9
- Efinaconazole 144230-50-2
- Efinaconazole 133775-25-4
- Efinaconazole 127000-90-2
- Gadoterate Meglumine
- Mirabegron
- Luliconazole 98873-55-3
- Luliconazole 126534-31-4
- Atazanavir sulfate
- Bortezomib 179324-87-9
- Bortezomib 114457-94-2
- Bortezomib 205393-22-2
- Brinzolamide
- Rivaroxaban Intermediate 446292-08-6
- Rivaroxaban Intermediate 446292-07-5
- Cinacalcet Hydrochloride 1005450-55-4
- Cinacalcet Hydrochloride 585-50-2
- Eletriptan Intermediate
- Indacaterol intermediate 312753-53-0
- Indacaterol intermediate 173140-90-4
- Sitagliptin Intermediate
- Fosanavir Calcium Intermediate
Popular information
Smoking cessation drugs Varenicline hydrochloride 230615-23-3
【Catalog number】AP0507
【CAS #】 375815-87-5
【Molecular formula】C17H19N3O6
【Product Brief】 US-DMF No. 030182 varenic acid tartrate, English name is varenicline tartrate, CAS 375815-87-5.
Varenicline hydrochloride
CAS # 230615-23-3
Alias 6,7,8,9-tetrahydro-6,10-methyl bridge-6H-pyrazino [2,3-H] [3] benzoazepine hydrochloride; varnaclan hydrochloride
Catalog number AP0506
CAS # 230615-23-3
Molecular formula C13H14ClN3
Molecular weight 247.72
Structural formula
Product introduction
CAS 230615-23-3 Varencline hydrochloride, English name Varenicline hydrochloride, American Chemical Abstracts Registry Number CAS 230615-23-3.
Valenkelin hydrochloride (cas 230615-23-3) is FDA approved and can be used as a non-nicotine smoking cessation drug. The test results show that after drug treatment, the success rate of quitting smoking for six months is 30%. When smoking, nicotine acts as a receptor in the brain, bringing satisfaction to smokers. Varenicline hydrochlorid acts on nicotine-affected areas of the human brain, exerting effects similar to nicotine, soothing withdrawal symptoms during smoking, and preventing The effects of nicotine on the human body when you quit smoking again.
VIWIT 沪ICP备12014533号-1
